| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD99 |
| Uniprot No | P14209 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-122aa |
| 氨基酸序列 | DGGFDLSDALPDNENKKPTAIPKKPSAGDDFDLGDAVVDGENDDPRPPNP PKPMPNPNPNHPSSSGSFSDADLADGVSGGEGKGGSDGGGSHRKEGEEAD VDDIEGRMDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD99重组蛋白的3篇参考文献示例(内容基于公开研究概括，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*CD99 regulates the expansion and activity of human T cells*
**作者**：Smith A, et al.
**摘要**：研究报道了重组CD99蛋白通过调节T细胞受体信号通路，促进T细胞活化和增殖，揭示了其在免疫应答中的潜在调控作用。
---
2. **文献名称**：*Recombinant CD99 suppresses osteosarcoma cell migration via ERK1/2 pathway inhibition*
**作者**：Chen L, et al.
**摘要**：该研究利用重组CD99蛋白处理骨肉瘤细胞，发现其能显著抑制细胞迁移和侵袭能力，机制可能与下调ERK信号通路相关。
---
3. **文献名称**：*Expression and purification of functional CD99 ectodomain in mammalian cells for antibody screening*
**作者**：Wang Y, et al.
**摘要**：文章优化了CD99重组蛋白在哺乳动物细胞中的表达和纯化方法，并验证其结合特异性，为开发靶向CD99的抗体药物提供了技术基础。
---
**提示**：以上为模拟示例，建议通过PubMed、Google Scholar等平台搜索关键词“CD99 recombinant protein”或“recombinant CD99”获取真实文献。
CD99 recombinant protein is derived from the CD99 antigen, a highly conserved 32-kDa transmembrane glycoprotein encoded by the *MIC2* gene located on the X and Y chromosomes. Initially identified as a surface marker for T cells and thymocytes, CD99 plays diverse roles in cellular processes such as adhesion, migration, apoptosis, and immune regulation. Its extracellular domain mediates homophilic interactions, influencing T-cell activation, leukocyte transendothelial migration, and hematopoietic cell differentiation. Dysregulation of CD99 is implicated in pathological conditions, including Ewing sarcoma, acute leukemias, and inflammatory disorders, where it can modulate cell proliferation or metastasis.
Recombinant CD99 protein is engineered through heterologous expression systems (e.g., *E. coli*, mammalian cells) to study its structure-function relationships or therapeutic potential. The protein often retains key functional epitopes, enabling research on its role in immune modulation, tumor biology, and cell signaling. For instance, CD99-targeting antibodies or recombinant ligands have been explored to inhibit cancer metastasis or modulate immune responses. However, challenges remain in optimizing post-translational modifications (e.g., glycosylation) critical for its bioactivity.
Recent studies highlight CD99’s dual roles: in some cancers, it acts as a tumor suppressor by inducing apoptosis, while in others, it promotes invasiveness via interactions with heparan sulfate proteoglycans (HSPGs) or cytoskeletal regulators. Recombinant CD99 tools are vital for dissecting these context-dependent mechanisms and developing diagnostic or therapeutic strategies. Ongoing research focuses on leveraging its immunomodulatory properties in chimeric antigen receptor (CAR) T-cell therapies or as a biomarker for minimal residual disease monitoring. Despite progress, comprehensive understanding of its signaling networks and clinical translation requires further exploration.
×
